Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05772169 · ClinicalTrials.gov registry record · Phase 4
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
A Phase 4 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,113
- Enrollment target
NCT05772169 is a Phase 4 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 1,113 participants.
The verdict
NCT05772169, a Phase 4 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,113 participants
- Enrollment target
Study Summary
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to control T2D despite receiving standard of care therapies.
Interventions
- DRUG Mifepristone 300 MG [Korlym]
- DRUG Placebo for mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,113 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2024-12-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05772169
The ClinicalTrials.gov registry entry for NCT05772169 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mifepristone 300 MG [Korlym] is the first listed.
NCT05772169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05772169 about?
NCT05772169 is a clinical study titled "Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)". This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a ...
What is the current status of trial NCT05772169?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,113 participants. The study started on 2023-03-31. Estimated completion is 2024-12-18.
What interventions are being tested in trial NCT05772169?
The interventions under investigation include: Mifepristone 300 MG [Korlym] (DRUG), Placebo for mifepristone (DRUG).
Who is sponsoring clinical trial NCT05772169?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.